New combo therapy aims to shrink lung tumors in hard-to-treat patients
Disease control
Not yet recruiting
This study tests a new drug (ILKN421H) combined with an existing immunotherapy (pembrolizumab) in 80 adults with advanced non-small cell lung cancer. It includes patients who have not had prior treatment or whose cancer worsened after immunotherapy. The goal is to see if the comb…
Phase: PHASE2 • Sponsor: iLeukon Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 16:00 UTC